133 related articles for article (PubMed ID: 2993536)
1. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: a Southwest Oncology Group Study.
Taylor SA; McCracken JD; Eyre HJ; O'Bryan RM; Neilan BA
J Neurooncol; 1985; 3(2):131-5. PubMed ID: 2993536
[TBL] [Abstract][Full Text] [Related]
2. Phase I-II evaluation of intra-arterial diaziquone for recurrent malignant astrocytomas.
Greenberg HS; Ensminger WD; Layton PB; Gebarski S; Meyer M; Chaffee B; Bender JF; Grillo-Lopez AJ
Cancer Treat Rep; 1986 Mar; 70(3):353-7. PubMed ID: 3006913
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. Preliminary report.
Decker DA; Al Sarraf M; Kresge C; Austin D; Wilner HI
J Neurooncol; 1985; 3(1):19-21. PubMed ID: 2987424
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of 24 hour intravenous AZQ in recurrent primary brain tumors.
Chamberlain MC; Prados MD; Silver P; Levin VA
J Neurooncol; 1988 Dec; 6(4):319-23. PubMed ID: 3221259
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, diaziquone) in recurrent human primary brain tumors.
Eagan RT; Dinapoli RP; Cascino TL; Scheithauer B; O'Neill BP; O'Fallon JR
J Neurooncol; 1987; 5(4):309-14. PubMed ID: 3440875
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 5-day continuous infusion aziridinylbenzoquinone (AZQ, diazaquone, NSC 182968).
Sigman LM; Van Echo DA; Whitacre MY; Aisner J; Budman DA; Shulman P
Am J Clin Oncol; 1986 Feb; 9(1):79-82. PubMed ID: 3953494
[TBL] [Abstract][Full Text] [Related]
7. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council.
Haid M; Khandekar JD; Christ M; Johnson CM; Miller SJ; Locker GY; Merrill JM; Reisel H; Hatfield A; Lanzotti V
Cancer; 1985 Sep; 56(6):1311-5. PubMed ID: 4027870
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with recurrent primary brain tumors with AZQ.
Schold SC; Friedman HS; Bjornsson TD; Falletta JM
Neurology; 1984 May; 34(5):615-9. PubMed ID: 6538653
[TBL] [Abstract][Full Text] [Related]
9. Preliminary communication--treatment of primary brain tumors recurrent after irradiation with aziridinylbenzoquinone (AZQ;NSC-182986).
Eagan RT; Dinapoli RP; Hermann RC; Groover RV; Layton DD
Am J Clin Oncol; 1983 Oct; 6(5):577-8. PubMed ID: 6613923
[TBL] [Abstract][Full Text] [Related]
10. Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors. A Pediatric Oncology Group phase II study.
Castleberry RP; Ragab AH; Steuber CP; Kamen B; Toledano S; Starling K; Norris D; Burger P; Krischer JP
Invest New Drugs; 1990 Nov; 8(4):401-6. PubMed ID: 2084075
[TBL] [Abstract][Full Text] [Related]
11. Response rate and toxicity with aziridinylbenzoquinone in patients with recurrent gliomas. A progress report.
Tapazoglou E; Kish J; Ensley J; Al-Sarraf M
Am J Clin Oncol; 1988 Aug; 11(4):474-8. PubMed ID: 3407628
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of aziridinylbenzoquinone in refractory lymphoma.
Case DC; Hayes DM
Cancer Treat Rep; 1983 Nov; 67(11):993-6. PubMed ID: 6357437
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of aziridinylbenzoquinone (AZQ) in patients with refractory small cell carcinoma of the lung.
Fuks JZ; Aisner J; Van Echo DA; Levitt M; Ihde DC; Carney D; Wiernik PH
Am J Clin Oncol; 1983 Apr; 6(2):171-3. PubMed ID: 6299094
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical evaluation of AZQ in metastatic breast cancer.
Yap HY; Bedikian AY; Schell FC; Blumenschein GR; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):31-3. PubMed ID: 6837505
[TBL] [Abstract][Full Text] [Related]
16. Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma.
Maral J; Poisson M; Pertuiset BF; Mashaly P; Weil M; Jacquillat C; Grillo-Lopez AJ
J Neurooncol; 1985; 3(3):245-9. PubMed ID: 4056853
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
18. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma.
Creagan ET; Schutt AJ; Ahmann DL; Green SJ
Cancer Treat Rep; 1982 Dec; 66(12):2089-90. PubMed ID: 7139650
[TBL] [Abstract][Full Text] [Related]
20. AZQ therapy in patients with disseminated malignant melanoma.
Yap BS; Bedikian AY; Burgess MA; Bodey GP
Am J Clin Oncol; 1982 Dec; 5(6):623-5. PubMed ID: 7165003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
